Cargando…

Sitagliptin and heart failure hospitalization in patients with type 2 diabetes

This study evaluated the risk of heart failure hospitalization in a 1:1 matched pair sample of sitagliptin ever and never users derived from the Taiwan's National Health Insurance. A total of 85,859 ever users and 85,859 never users matched on 8 digits of propensity score were followed for the...

Descripción completa

Detalles Bibliográficos
Autor principal:	Tseng, Chin-Hsiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308758/ https://www.ncbi.nlm.nih.gov/pubmed/27409676 http://dx.doi.org/10.18632/oncotarget.10507

Ejemplares similares

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2016)

Sitagliptin and oral cancer risk in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2017)

Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2016)

Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis
por: Tseng, Chin‐Hsiao
Publicado: (2019)

Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study
por: Hung, Yi-Chih, et al.
Publicado: (2016)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Metformin and lung cancer risk in patients with type 2 diabetes mellitus
por: Tseng, Chin-Hsiao
Publicado: (2017)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh, Ching-Jung, et al.
Publicado: (2014)

Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus
por: Tseng, Chin-Hsiao
Publicado: (2016)

Metformin use and cervical cancer risk in female patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2016)

Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus
por: Tseng, Chin-Hsiao
Publicado: (2016)

Metformin may reduce oral cancer risk in patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2015)

Sex-Related Differences in Sitagliptin Treatment in Type 2 Diabetes: Results from the PROLOGUE Trial
por: Wu, Xilin, et al.
Publicado: (2022)

Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients
por: Sun, Yue, et al.
Publicado: (2020)

Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2019)

Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin
por: Jameshorani, Maryam, et al.
Publicado: (2017)

Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
por: Wilson, Jessica R., et al.
Publicado: (2017)

Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus
por: Tseng, Chin-Hsiao
Publicado: (2016)

The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation
por: Mita, Tomoya, et al.
Publicado: (2017)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Protective Effect of Sitagliptin and Rosuvastatin Combination on Vascular Endothelial Dysfunction in Type-2 Diabetes
por: Nade, Vandana S., et al.
Publicado: (2015)

A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus
por: Williams, Brent A., et al.
Publicado: (2019)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
por: Mori, Hiroko, et al.
Publicado: (2013)

Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes
por: Ohmura, Hirotoshi, et al.
Publicado: (2015)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto, Seitaro, et al.
Publicado: (2015)

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
por: Zeng, De-kang, et al.
Publicado: (2019)

Long-term effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension: results from the PROLOGUE study
por: Ye, Ziliang, et al.
Publicado: (2017)

Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wan, Heng, et al.
Publicado: (2016)

The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF study
por: Carbone, Salvatore, et al.
Publicado: (2020)

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
por: Nauck, Michael A., et al.
Publicado: (2019)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
por: Williams-Herman, Debora, et al.
Publicado: (2008)

Genome-Wide Transcriptome Analysis in Type 2 Diabetes Patients Treated by Sitagliptin
por: Ma, Rui, et al.
Publicado: (2022)

Metformin Use Is Associated With a Lower Incidence of Hospitalization for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
por: Tseng, Chin-Hsiao
Publicado: (2021)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
por: Gudipaty, Lalitha, et al.
Publicado: (2014)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Metformin and Risk of Hypertension in Taiwanese Patients With Type 2 Diabetes Mellitus
por: Tseng, Chin‐Hsiao
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4bs137m66go0kk3dr2meqf1gpm